On the contrary, doxorubicin treatment of HT29-dx and HT29-iNOS- cells failed to induce CRT translocation, did not change the uptake of the tumour and had no effect on the alloantigen presenting activity of DCs. This evidence concerns the gene NOS2 and neoplasm.